PMID- 28603135
OWN - NLM
STAT- MEDLINE
DCOM- 20171103
LR  - 20181202
IS  - 1011-601X (Print)
IS  - 1011-601X (Linking)
VI  - 30
IP  - 1
DP  - 2017 Jan
TI  - Report: Impact of drug combination of clopidogrel and pantoprazole In the 
      prognosis of patients with transient ischemic attack.
PG  - 217-221
AB  - The study aimed to investigate the impact of clopidogrel combined with proton 
      pump inhibitors (PPI) pantoprazole treatment on the prognosis of patients with 
      transient ischemic attack (TIA). A total of 478 cases of TIA patients treated 
      with clopidogrel were randomly assigned half to clopidogrel combined with 
      pantoprazole treatment and the control groups (clopidogrel treatment alone) from 
      January 2012 to January 20l4. The platelet aggregation before and after treatment 
      and cerebrovascular events incidence within 90 days were compared and analyzed. 
      Multivariate analysis was used to estimate the incidence of cerebrovascular 
      events within 90 days. The platelet aggregation rate before treatment was 
      73.2+/-6.1% in the treatment group, 74.1+/-8.8% in the control group. The platelet 
      aggregation rate after treatment was 38.1+/-10.7% in the treatment group, 36.8+/-9.7% 
      in the control group. The platelet aggregation before and after treatments 
      between the two groups had not significant difference (P>0.05). The incidence of 
      cerebrovascular events within 90 days (11.7% in the treatment group, 9.6% in the 
      control group) between the two groups had not significant difference (P>0.05). 
      Multivariate analysis showed that the incidence of cerebrovascular events within 
      90 day was associated with hypertension (P=0.008), diabetes (P=0.000), 
      hyperlipidemia (P=0.002) and ABCD2 score >3 points (P=0.000). Clopidogrel 
      combined with pantoprazole treatment had no significant effect on the prognosis 
      of TIA patients.
FAU - Lu, Min
AU  - Lu M
AD  - Department of Neurology, Nanjing First Hospital, Nanjing Medical University, 
      Nanjing, China.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Pakistan
TA  - Pak J Pharm Sci
JT  - Pakistan journal of pharmaceutical sciences
JID - 9426356
RN  - 0 (2-Pyridinylmethylsulfinylbenzimidazoles)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Proton Pump Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - D8TST4O562 (Pantoprazole)
RN  - EC 1.14.14.1 (CYP2C19 protein, human)
RN  - EC 1.14.14.1 (Cytochrome P-450 CYP2C19)
RN  - OM90ZUW7M1 (Ticlopidine)
SB  - IM
MH  - 2-Pyridinylmethylsulfinylbenzimidazoles/adverse effects/*therapeutic use
MH  - Aged
MH  - Aged, 80 and over
MH  - Chi-Square Distribution
MH  - China/epidemiology
MH  - Clopidogrel
MH  - Cytochrome P-450 CYP2C19/genetics/metabolism
MH  - Disease Progression
MH  - Drug Therapy, Combination
MH  - Female
MH  - Genotype
MH  - Humans
MH  - Incidence
MH  - Ischemic Attack, Transient/blood/diagnosis/*drug therapy/epidemiology
MH  - Logistic Models
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Pantoprazole
MH  - Pharmacogenomic Variants
MH  - Phenotype
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Platelet Function Tests
MH  - Proton Pump Inhibitors/adverse effects/*therapeutic use
MH  - Risk Factors
MH  - Stroke/blood/diagnosis/epidemiology/*prevention & control
MH  - Ticlopidine/adverse effects/*analogs & derivatives/therapeutic use
MH  - Time Factors
MH  - Treatment Outcome
EDAT- 2017/06/13 06:00
MHDA- 2017/11/04 06:00
CRDT- 2017/06/13 06:00
PHST- 2017/06/13 06:00 [entrez]
PHST- 2017/06/13 06:00 [pubmed]
PHST- 2017/11/04 06:00 [medline]
PST - ppublish
SO  - Pak J Pharm Sci. 2017 Jan;30(1):217-221.